Novo Nordisk is under pressure from cheap copycats, a Trump pricing deal, and Lilly's fast-growing Zepbound juggernaut.
Hims & Hers Health, Inc. could see more upside in partnerships and international expansion. Click here to read an analysis of ...
Woman's World on MSN
Dr Blitz: TrumpRx Deal for Wegovy and Zepbound ‘Just What the Doctor Ordered'
After writing dozens of GLP-1 articles over the past year, one issue that consistently comes up is the affordability of ...
Pfizer Inc. acquires Metsera, Inc., beating Novo Nordisk, for up to $86.25/share. Click for my analysis of the deal and what ...
Medpage Today on MSN
Semaglutide's MASH Benefits Extend Beyond Weight Loss
WASHINGTON -- Semaglutide (Wegovy) improved liver inflammation and fibrosis in patients with metabolic dysfunction-associated ...
Injectable weight-loss drugs can reduce the risk of serious cardiovascular events for people with type 2 diabetes.
New versions of drugs like Wegovy, Ozempic, Mounjaro and Zepbound, including pills, will be easier to take, more effective ...
Injectable weight-loss drugs can reduce the risk of serious cardiovascular events for people with type 2 diabetes. Researchers at the Technical University of Munich (TUM) and Harvard Medical School ...
The White Houes may have struck a deal with Eli Lilly and Novo Nordisk last week to lower the costs of their weight loss ...
Everyday Health on MSN
Experimental Obesity Drug Could Soon Compete With Wegovy and Zepbound
Drugmaker Eli Lilly said it would soon start late-stage trials for eloralintide, a drug mimicking the pancreatic hormone ...
An experiment at the State University of Campinas found that FGF19, a substance produced in the intestine, acts on specific ...
However, science is now reopening doors once closed, and therapies previously dismissed are being reconsidered with fresh ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback